Markela Koniordou

Markela Koniordou

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MBMounia Beloueche-Babari
Mounia Beloueche-Babari
SWSlawomir Wantuch
Slawomir Wantuch
TGTeresa Casals Galobart
Teresa Casals Galobart
MKMarkela Koniordou
Markela Koniordou
HPHarold G. Parkes
Harold G. Parkes
MLMartin O. Leach
Martin O. Leach
Monocarboxylate transporters (MCT) modulate tumor cell metabolism and offer promising therapeutic targets for cancer treatment. Understanding the impact of MCT blockade on tumor cell metabolism may help develop combination strategies or identify pharmacodynamic biomarkers to support the clinical development of MCT inhibitors now in clinical trials. In this study, we assessed the impact of the MCT1 inhibitor AZD3965 on cancer cell metabolism in vitro and in vivo. Exposing human lymphoma and colon carcinoma cells to AZD3965 increased MCT4-dependent accumulation of intracellular lactate, inhibiting monocarboxylate influx and efflux. AZD3965 also increased the levels of TCA cycle–related metabolites and 13C-glucose mitochondrial metabolism, enhancing oxidative pyruvate dehydrogenase and anaplerotic pyruvate carboxylase fluxes. Increased mitochondrial metabolism was necessary to maintain cell survival under drug stress. These effects were counteracted by coadministration of the mitochondrial complex I inhibitor metformin and the mitochondrial pyruvate carrier inhibitor UK5099. Improved bioenergetics were confirmed in vivo after dosing with AZD3965 in mouse xenograft models of human lymphoma. Our results reveal new metabolic consequences of MCT1 inhibition that might be exploited for therapeutic and pharmacodynamic purposes. Cancer Res; 77(21); 5913–24. ©2017 AACR.

29 January 2021 in Global Health Research and Policy
Verified
Journal Article
Open access
PDF file
GKGeorgia Kourlaba
Georgia Kourlaba
EKEleni Kourkouni
Eleni Kourkouni
SMStefania Maistreli
Stefania Maistreli
CTChristina-Grammatiki Tsopela
Christina-Grammatiki Tsopela
NMNafsika-Maria Molocha
Nafsika-Maria Molocha
TZTheoklis E. Zaoutis
Theoklis E. Zaoutis
Background: Epidemiological data indicate that a large part of population needs to be vaccinated to achieve herd immunity. Hence, it is of high importance for public health officials to know whether people are going to get vaccinated for COVID-19. The objective of the present study was to examine the willingness of adult residents in Greece to receive a COVID-19 vaccine. Methods: A cross-sectional was survey conducted among the adult general population of Greece between April 28, 2020 to May 03, 2020 (last week of lockdown), using a mixed methodology for data collection: Computer Assisted Telephone Interviewing (CATI) and Computer Assisted web Interviewing (CAWI). Using a sample size calculator, the target sample size was found to be around 1000 respondents. To ensure a nationally representative sample of the urban/rural population according to the Greek census 2011, a proportionate stratified by region systematic sampling procedure was used to recruit particpants. Data collection was guided through a structured questionnaire. Regarding willingness to COVID-19 vaccination, participants were asked to answer the following question: “If there was a vaccine available for the novel coronavirus, would you do it? ” Results: Of 1004 respondents only 57.7% stated that they are going to get vaccinated for COVID-19. Respondents aged > 65 years old, those who either themselves or a member of their household belonged to a vulnerable group, those believing that the COVID-19 virus was not developed in laboratories by humans, those believing that coronavirus is far more contagious and lethal compared to the H1N1 virus, and those believing that next waves are coming were statistically significantly more likely to be willing to get a COVID-19 vaccine. Higher knowledge score regarding symptoms, transmission routes and prevention and control measures against COVID-19 was significantly associated with higher willingness of respondents to get vaccinated. Conclusion: A significant proportion of individuals in the general population are unwilling to receive a COVID-19 vaccine, stressing the need for public health officials to take immediate awareness-raising measures.

13 January 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CGCarles Gaston-Massuet
Carles Gaston-Massuet
MMMark J. McCabe
Mark J. McCabe
VSValeria Scagliotti
Valeria Scagliotti
RYRodrigo M. Young
Rodrigo M. Young
GCGabriela Carreno
Gabriela Carreno
JMJuan Pedro Martinez-Barbera
Juan Pedro Martinez-Barbera
Significance: The relevance of transcription factor 7-like 1 (TCF7L1) during hypothalamo–pituitary (HP) axis development remains unknown. Using mouse genetics, we show that TCF7L1 acts as a transcriptional repressor to regulate the expression of the hypothalamic signals involved in pituitary formation. In addition, we screened a cohort of human patients with forebrain and/or pituitary defects and report two independent missense variants, p.R92P and p.R400Q, in human TCF7L1. Functional studies in vitro and rescue experiments in zebrafish mutants deficient for tcf7l1a and tcf7l1b show that the p.R92P and p.R400Q variants exhibit reduced repressing activity compared with wild-type TCF7L1. In summary, we identify TCF7L1 as a determinant for the establishment of HP axis development and as a potential candidate gene to be mutated in congenital hypopituitarism.

2 June 2022 in Vaccine
Verified
Journal Article
Open access
JSJon Salmanton-García
Jon Salmanton-García
FSFiona A. Stewart
Fiona A. Stewart
SHSarah Heringer
Sarah Heringer
MKMarkela Koniordou
Markela Koniordou
EÁElena Álvarez-Barco
Elena Álvarez-Barco
ZPZoi-Dorothea Pana
Zoi-Dorothea Pana
The coronavirus disease 2019 (COVID-19) pandemic has evidenced the key role of vaccine design, obtention, production and administration to successfully fight against infectious diseases and to provide efficient remedies for the citizens. Although clinical trials were rapidly established during this pandemic, identifying suitable study subjects can be challenging. For this reason, the University Hospital Cologne established a volunteer registry for participation in clinical trials first in Germany, which has now been incorporated into the European VACCELERATE clinical trials network and grew to a European Volunteer Registry. As such, VACCELERATE’s Volunteer Registry aims to become a common entry point for potential volunteers in future clinical trials in Europe. Interested volunteers who would like to register for clinical trials in the VACCELERATE Volunteer Registry can access the registration questionnaire via http://www.vaccelerate.eu/volunteer-registry. Potential volunteers are requested to provide their current country and area of residence, contact information, including first and last name and e-mail address, age, gender, comorbidities, previous SARS-CoV-2 infection and vaccination status, and maximum distance willing to travel to a clinical trial site. The registry is open to both adults and children, complying with national legal consent requirements. As of May 2022, the questionnaire is available in 12 countries and 14 languages. Up to date, more than 36,000 volunteers have registered, mainly from Germany. Within the first year since its establishment, the VACCELERATE Volunteer Registry has matched more than 15,000 volunteers to clinical trials. The VACCELERATE Volunteer Registry will be launched in further European countries in the coming months. The VACCELERATE Volunteer Registry is an active single-entry point for European residents interested in COVID-19 clinical trials participation in 12 countries (i.e., Austria, Cyprus, Germany, Greece, Ireland, Lithuania, Norway, Portugal, Spain, Sweden and Turkey). To date, more than 15,000 registered individuals have been connected to clinical trials in Germany alone. The registry is currently in the implementation phase in 5 additional countries (i.e., Belgium, Czech Republic, Hungary, Israel and the Netherlands).

1 March 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MKMarkela Koniordou
Markela Koniordou
SPStephen Patterson
Stephen Patterson
SWSusan Wyllie
Susan Wyllie
KSKarin Seifert
Karin Seifert
This study characterized the in vitro potencies of antileishmanial agents against intracellular Leishmania donovani amastigotes in primary human macrophages, obtained with or without CD14-positive monocyte enrichment, phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells, and mouse peritoneal exudate macrophages (PEMs). Host cell-dependent potency was confirmed for pentavalent and trivalent antimony. Fexinidazole was inactive against intracellular amastigotes across the host cell panel. Fexinidazole sulfone, ( R )-PA-824, ( S )-PA-824, and VL-2098 displayed similar potency in all of the host cells tested.

24 June 2021 in Pneumon
Verified
Journal Article
Open access
IKIoannis Kopsidas
Ioannis Kopsidas
ECEvangelia Chorianopoulou
Evangelia Chorianopoulou
EKEleni Kourkouni
Eleni Kourkouni
CTChristos Triantafyllou
Christos Triantafyllou
NMNafsika-Maria Molocha
Nafsika-Maria Molocha
GKGeorgia Kourlaba
Georgia Kourlaba
Introduction: Vaccination against the flu is the best method for the prevention of illness by influenza viruses. The objective of this study was to assess the impact of the COVID-19 pandemic on the seasonal influenza vaccination attitudes in Greece and to identify factors associated with a...